Clinical trials: Partial
Partial-edentulism
Clinical Evaluation of NiTiDent Tuah Porous NiTi Dental Implants
The purpose of this prospective, open-label, randomized, double arm multicenter study is to evaluate the safety and clinical performance of a newly developed NiTiDent Tuah porous NiTi dental implant (from Nitium Technology Sdn…
- Trial name
- NCT04618055
- Testing
- NiTiDent Tuah Porous NiTi Dental Implants, Control Dental Implant Systems
- Where
- 3 sites in Malaysia
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Nitium Technology Sdn Bhd
Chronic Spontaneous Urticaria
Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)
Primary Objective: This study aimed to demonstrate the efficacy of dupilumab in study participants with CSU who remained symptomatic despite the use of H1 antihistamine (Study A and C: omalizumab naïve; Study B: omalizumab…
- Trial name
- NCT04180488
- Testing
- Dupilumab SAR231893, non sedating H1-antihistamine
- Where
- 98 sites in United States, Argentina and 9 more
- Volunteers
- 397 people
- Sponsor
- Sanofi
Amputation; Traumatic, Hand
To Assess the Utility of the Point Partial in a Clinical Take-home Study of Partial Hand Amputees
This study will allow us to assess whether the Point Partial confers functional and psychological benefit to persons with partial finger amputations in an unconstrained environment.
- Trial name
- NCT05012683
- Testing
- Point Partial
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Point Designs
Focal Epilepsy, Intraoperative Monitoring
Evaluation of New Flexible High-density Intra-operative ECoG Electrodes for Epilepsy Surgery. ( EpiGrid )
The objective of this prospective interventional monocentric clinical investigation is to evaluate the feasibility and performance of the flexible high-density SOFT ECoG electrode grids, manufactured by Neurosoft Bioelectronics…
- Trial name
- EpiGrid (NCT06205160)
- Testing
- SOFT ECoG subdural grid electrode
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Neurosoft Bioelectronics SA
Hepatitis C
A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)
This study is being done to find out if the addition of boceprevir to standard of care (SOC) treatment with peginterferon alfa-2b (PegIFN-2b) + ribavirin (RBV) is effective for participants with chronic hepatitis C (CHC) genotype…
- Trial name
- NCT01756079
- Testing
- boceprevir, PegIFN-2b, RBV
- Volunteers
- 58 people
- Sponsor
- Merck Sharp & Dohme LLC
Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults
The purpose of this study is to determine whether ketamine-induced brain activity changes are modulated by TAK-063 administration using neuroimaging battery tests.
- Trial name
- NCT01892189
- Testing
- Ketamine, TAK-063
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Takeda
Sprains and Strains, Pain
A Study of the Efficacy and Safety of Tramadol HCl/Acetaminophen, Hydrocodone Bitartrate/Acetaminophen and Placebo in Patients With Pain From an Ankle Sprain With a Partial Torn Ligament
The purpose of this study is to explore the pain-relieving effects and safety of two analgesic treatment regimens as compared to placebo in patients experiencing acute musculoskeletal pain.
- Trial name
- NCT00236535
- Volunteers
- 603 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hypercholesterolemia
Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects
Primary Objective: To assess the pharmacodynamic profile of alirocumab (SAR236553/REGN727) administered either alone or on top of ezetimibe or fenofibrate, based on low-density lipoprotein -cholesterol (LDL-C).
- Trial name
- NCT01723735
- Testing
- Alirocumab, Ezetimibe, Fenofibrate
- Where
- 2 sites in France
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Sanofi
Kidney Neoplasm, Nephrectomy
Evaluation of 'RUS NE' in Robot-Assisted Partial Nephrectomy: Efficacy, Safety, and Stability
This study is a retrospective and prospective comparative study evaluating the efficacy, safety, and stability of the surgical navigation system 'RUS NE' in robot-assisted partial nephrectomy.
- Conditions
- Kidney Neoplasm, Nephrectomy, Surgical Navigation Systems, Renal Mass
- Trial name
- HTK_002 (NCT06945640)
- Testing
- RUS NE
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Hutom Corp
Growth Hormone Deficiency
Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents
To evaluate in boys and girls the improvement in body composition under GH treatment in adolescents with CO-GHD who remain partially GHD after GH discontinuation.
- Trial name
- TAUBER (NCT00156143)
- Testing
- Blood sample, Radiography
- Volunteers
- 90 people
- Sponsor
- Pfizer
Focal Epilepsy
A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy
The main purpose of this study is to investigate effects of Lu AG06466 on seizure activity after increasing daily doses during 4 weeks in participants with an implanted responsive neurostimulation system.
- Trial name
- NCT05081518
- Testing
- Lu AG06466
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- H. Lundbeck A/S
Burn Wounds
SWC for Treatment of Superficial Partial-Thickness Burns
The purpose of this study is to test the safety and effectiveness of SynePure™ Wound Cleanser when used in combination with Catasyn™ Advanced Technology Hydrogel for the treatment of superficial partial-thickness burn wounds.
- Trial name
- NCT05877638
- Testing
- SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel, SILVADENE Cream 1% (silver sulfadiazine)
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Synedgen, Inc.
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo
The Purpose of this study is to evaluate the 24-hour spirometry effect Forced Expiratory Volume in One second (FEV1) of 3 doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the end of a 28-day treatment period in…
- Trial name
- NCT01072149
- Testing
- Fluticasone Furoate (FF)/GW642444 Inhalation Powder
- Where
- 8 sites in United States
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Epilepsy
Study in Pediatric Subjects With Epilepsy
This is an open-label study to evaluate the pharmacokinetics, safety and tolerability of ezogabine/retigabine in subjects aged 12 years to less than 18 years with uncontrolled partial onset seizures or Lennos-Gastaut syndrome.
- Trial name
- NCT01494584
- Testing
- ezogabine/retigabine
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- GlaxoSmithKline
Gastrointestinal Stromal Tumors
Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
To provide study drug to patients that benefit from treatment judged by the investigator - to obtain additional long-term safety and efficacy data of this combination regimen in GIST
- Trial name
- NCT00441155
- Testing
- Nilotinib, Imatinib
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy, Partial, Motor, Epilepsy, Complex Partial
An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures
The purpose of this study is to obtain long-term safety and tolerability information on carisbamate as add-on therapy for the treatment of partial onset seizures in patients with epilepsy.
- Conditions
- Epilepsy, Partial, Motor, Epilepsy, Complex Partial, Epilepsy, Simple Partial, Focal Motor Epilepsy
- Trial name
- NCT00744731
- Testing
- carisbamate
- Volunteers
- 403 people
- Sponsor
- SK Life Science, Inc.
Hypertension, Hyperlipidemia
A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Atorvastatin in Healthy Male Volunteers.
The purpose of this study is to evaluate the Pharmacokinetics and Safety / Tolerability of Fimasartan and Atorvastatin in Healthy Male volunteers.
- Trial name
- NCT02994745
- Testing
- Fimasartan, Atorvastatin
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Neuroblastoma
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and…
- Trial name
- NCT03363373
- Testing
- GM-CSF + Naxitamab
- Where
- 20 sites in United States, Canada and 7 more
- Volunteers
- 122 people
- Sponsor
- Y-mAbs Therapeutics
Epilepsy
Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic
This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.
- Trial name
- NCT01091662
- Testing
- Eslicarbazepine acetate 1600 mg, Eslicarbazepine acetate 1200 mg
- Where
- 62 sites in United States, Bulgaria and 3 more
- Volunteers
- 172 people
- Sponsor
- Sumitomo Pharma America, Inc.
Seizures
Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures
The purpose of the study is to evaluate the effectiveness and safety of adjunctive RWJ-333369 at a dose of 200 or 400 mg/day in comparison with placebo in Korean and Japanese partial epilepsy patients who have poor seizure…
- Trial name
- NCT00697762
- Testing
- RWJ-333369
- Volunteers
- 56 people
- Sponsor
- SK Life Science, Inc.